Cisplatin Treatment for Adults With Advanced Pancreatic Cancer and DNA Repair Deficiency
Led by Fudan University · Updated on 2025-08-07
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to assess how well a cisplatin-based chemotherapy regimen works for patients with advanced pancreatic cancer who have homologous recombination deficiency HRD. This subgroup of patients has specific genetic changes that may make them respond differently to treatments. The study focuses on those whose cancer has progressed after at least one prior chemotherapy and evaluates whether cisplatin can improve progression-free survival and other important outcomes.
Participants will receive cisplatin at a dose of 25 mgm2 through a 30-minute intravenous infusion on days 1 and 8 of each 21-day cycle. Other chemotherapy drugs may be given following standard guidelines depending on individual cases. Patients whose cancer is sensitive to platinum treatment may be offered a PARP inhibitor after six months of cisplatin therapy. Treatment cycles and response will be closely monitored throughout the study.
During the trial, participants will be regularly assessed every four weeks for disease progression, tumor response, overall survival, and disease control using standard criteria. Researchers will conduct laboratory tests to ensure organ function and monitor safety. The study lasts until disease progression or other stopping criteria are met, with ongoing evaluations of treatment effects and participant well-being.
CONDITIONS
Brief Title
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Research Team
Y
Ying Yang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Ability to understand and willing to sign informed consent
Age between 18 and 80 years
ECOG performance status of 0 to 2
Histologically or cytologically confirmed advanced pancreatic adenocarcinoma
Tumor progression after at least one line of chemotherapy
Genetic or molecular confirmation of homologous recombination deficiency
At least one measurable lesion according to RECIST criteria
Expected survival of at least 3 months
Adequate organ function based on laboratory tests
Agreement to use adequate contraception if of childbearing potential
You will not qualify if you...
Pregnant or nursing women
Primary pancreatic cancer
Prior treatment with platinum drugs or PARP inhibitors
Diagnosis of non-adenocarcinoma pancreatic cancer by pathology
Inflammation of the digestive tract such as pancreatitis or cholecystitis
Severe or uncontrollable diseases affecting study compliance or results
Renal insufficiency or dialysis
Other serious illnesses that may endanger safety
Allergy to cisplatin or other platinum drugs
Unwillingness or inability to comply with study procedures
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Repeated 21-day cycles until disease progression or discontinuation
Participants receive a cisplatin based chemotherapy regimen, administered intravenously on Days 1 and 8 of each 21-day cycle, to treat advanced pancreatic cancer with homologous recombination deficiency.
Visits every 21 days for treatment administration and assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Phase 1b Study of 9-ING-41, Retifanlimab, and Modified FOLFIRINOX as Frontline Therapy for Advanced Pancreatic Adenocarcinoma
Study of ASP2138 Alone or With Pembrolizumab and Chemotherapy in Adults With Advanced or Metastatic Gastric, GEJ, or Pancreatic Cancer Expressing CLDN18.2
Study to Evaluate Safety and Effectiveness of ASP546C for Adults with CLDN18.2-Positive Advanced Gastroesophageal, Pancreatic, or Other Solid Tumors
Study of BMS-986340 Alone and With Nivolumab, Docetaxel, or Pumitamig in Adults With Advanced Solid Tumors
Phase 1 Study of CLSP-1025 Given by IV Infusion in Adults With Advanced Solid Tumors Having the p53 R175H Mutation and HLA-A*0201
Phase II Study of NovoTTF-200TP with Gemcitabine and Nab-Paclitaxel Before and After Surgery for Treatable Pancreatic Adenocarcinoma
Phase 1 Open-label Study Evaluating Safety and Early Activity of NT-175 Autologous T Cell Therapy in Adults With Advanced Cancers Positive for HLA-A*0201 and TP53 R175H Mutation
Phase 1 Study to Test Safety of PF-08046054 Alone and With Pembrolizumab in Advanced Solid Tumors
Investigating PF-08046876 Intravenous Treatment in Adults With Advanced Solid Tumors Including Bladder, Lung, Head and Neck, Esophageal, and Pancreatic Cancers
Phase III Study of Oral AMXI-5001 for Treating Advanced Cancers
Open Label Dose Escalation and Expansion in Adults
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
Eileen M O'Reilly, Jonathan W Lee, Mark Zalupski...